FlexShopper (NASDAQ:FPAY) reported quarterly sales of $30.47 million which missed the analyst consensus estimate of $31.60 million by 3.58 percent. This is a 0.72 percent decrease over sales of $30.69 million the same period last year.
SciSparc Closer To Phase II-B Trial Of Its Dronabinol Based Drug For The Treatment Of Tourette Syndrome
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has started the process of preparing for an Investigational New Drug Application (“IND”) with the U.S.
